Navigation Links
Arsenal Capital Partners Announces the Acquisition of Western Institutional Review Board

NEW YORK, March 1, 2012 /PRNewswire/ -- Arsenal Capital Partners, a leading New York-based private equity firm that invests in middle market healthcare, specialty industrial, and financial services companies, announced today the acquisition of Western Institutional Review Board (WIRB), a provider of information-based services which play an integral role in the clinical trial process for new drugs and medical devices.

WIRB is the leading independent institutional review board (IRB) services provider which operates federally mandated IRB panels.  IRBs review and approve the handling of ethical issues in research protocols before research involving human subjects can begin.  WIRB pioneered the concept of an independent IRB and is currently recognized as the "gold standard" in the industry.  The company has offices in the US and Canada and provides review services to research institutions, CROs and major sponsors in all 50 states and in more than 60 countries around the world. 

Stephen McLean, a Partner at Arsenal and Head of the firm's Healthcare Group, said, "We are delighted to invest in this important company.  WIRB has a long standing reputation of applying best practices in protecting human subjects involved in clinical research. Our investment in WIRB affords us the opportunity to apply Arsenal's unique healthcare industry resources to enhance and extend the essential IRB capabilities WIRB provides its clients."

"After evaluating a number of other options, we chose Arsenal Capital as our partners in creating the next chapter of our evolution.  We were impressed with Arsenal's expertise and capabilities in supporting our company's growth in the U.S. and globally. This is an extraordinarily positive development for our employees, our clients, and for the human subjects we protect," said Dudley Slater, CEO of WIRB.

Dr. Donald A. Deieso, Operating Partner in Arsenal's Healthcare Group will become Executive Chairman of WIRB.  Dr. Deieso commented, "The globalization of clinical research has created a number of new challenges for protecting human subjects.  WIRB will draw upon its longstanding knowledge of regulations and ethical practices to address these exciting challenges."

About Arsenal Capital Partners
Arsenal Capital Partners is a leading New York-based private equity firm that invests in middle market specialty industrial, healthcare and financial services companies.  Arsenal makes investments in sectors where the firm has significant prior knowledge and experience.  Arsenal targets businesses that have the potential for further value creation by working closely with management to accelerate growth and leverage the firm's operational improvement capabilities.  Arsenal currently has $800 million of committed equity capital.  For additional information on Arsenal Capital Partners, please visit

About Western Institutional Review Board
WIRB was founded in 1968 and is the leading provider of independent IRB, biosafety and other human protection services to the research institutions, CROs and major sponsors. The company has offices in the US and Canada and provides review services in all 50 states and in more than 60 countries around the world. For additional information on WIRB, please visit

Contact: Chris Tofalli
Chris Tofalli Public Relations, LLC

WIRB Contact
Monika Roberts

SOURCE Arsenal Capital Partners
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. bioMerieux Adds Methicillin-resistant Staphylococcus aureus (MRSA) Screening Tool to its Arsenal
2. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
3. Replidyne to Participate on Anti-infective Panel at RBC Capital Markets Healthcare Conference
4. Paul Capital Healthcare Purchases Additional Royalty Interest in GlaxoSmithKlines Rotarix(R)
5. Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials
6. Foundation Venture Capital Group Invests in UMDNJ Company Working to Improve Leukemia Treatments
7. BioInformatics, LLC New Report - Capitalizing on New Opportunities for Stem Cell Products, Now Available
8. Atlanta-based Med Tech Company CardioMEMS Raises Additional Capital to Advance its CHAMPION Clinical Trial for its Wireless Sensor System for Heart Failure Monitoring
9. Despite Limited Capital Equipment Purchases In 2009, The Global Powered Surgical Instrument Market Held Its Value At $800 Million
10. Baxa Addresses Health-System Capital Shortage With New Programs for IntelliFlowRx(TM) and IntelliFill i.v.(R)
11. New Fall Allergy Capitals(TM) Reveal the Most Challenging Cities for Allergy Sufferers
Post Your Comments:
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
(Date:6/23/2016)... BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a ... second affiliate in Latin America . ... ... ... ...
(Date:6/23/2016)... 23, 2016  Experian Health, the healthcare ... the patient payment and care experience, today ... products and services that will enhance the ... offerings. These award-winning solutions will enable healthcare ... compliant in an ever-changing environment and redefine ...
Breaking Medicine Technology:
(Date:6/26/2016)... Carolina (PRWEB) , ... June 26, 2016 , ... ... of a new product that was developed to enhance the health of felines. The ... centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can ... Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey ... cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
Breaking Medicine News(10 mins):